The FDA has issued a safety alert for some ranitidine medications, including the brand Zantac. The contaminant NDMA, which is classified as a probable human carcinogen, has been found in these medications. The FDA is not recommending that physicians advise their patients to stop these medication at this time, but, rather that they discuss alternate treatment options if patients want to discontinue ranitidine. If this is something you would like to do, please reach out to your physician to let him or her know you would like to discuss alternative treatment options.